Young Onset Type 2 Diabetes: a lost of protection of youth

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SAT 786-805-Diabetes & Obesity Therapeutics
Bench to Bedside
Saturday, June 15, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SAT-802
Abdulghani Habib Alsaeed*1, Maria Costantino2, Lynda Molyneaux3, Franziska Gisler-Limacher4, Franziska Gisler-Limacher4, Connie Luo4, Ted Wu4, Stephen Morris Twigg5, Dennise Yue4 and Jencia Wong6
1Riyadh Amed Forced Hosp, Riyadh, Central Region, Saudi Arabia, 2royal prince alfred hospital, 3Royal Prince Alfred Hospital, sydney, Australia, 4royal Prince Alfred Hospital, 5Univ of Sydney, Sydney NSW, Australia, 6Royal Prince Alfred Hospital, Camperdown NSW, Australia
Abdulghani Al-Saeed1,2, Maria Costantino1,3 , Lynda Molyneaux L1,3, Franziska Gisler-Limacher3 , Connie Luo1,3, Ted Wu1, Stephen M Twigg1,3, Dennis K Yue1,3,Jencia Wong1,3

¹ Diabetes Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia

²Riyadh Armed Force Hospital, Riyadh, Kingdom of Saudi Arabia

3Discipline of Medicine, University of Sydney, Sydney, NSW, Australia

Abstract

Aim: To compare the clinical characteristics and case fatality on Type 2 diabetes diagnosed between the age of 15–30 years to those diagnosed between 40–50 years of age, after matching for duration of diabetes. 

Methods: Data of 354 patients with young onset Type 2 diabetes collected over 20 years were compared to 1062 matched individuals with older onset Type 2 diabetes.  Case fatality was evaluated by cross-referencing against the National Death Index.  Further comparison was made between the deceased and the survivors of the young onset patients.

Results:  Young onset Type 2 diabetes died at an earlier age than their older onset counterpart, at a disadvantage of 16 years and after the same duration of diabetes, usually from vascular disease (50%, p=0.0001). Despite their younger age, they were equally affected by features of the metabolic syndrome when compared with the older onset individuals but were less treated for hypertension and dyslipidaemia (p<0.0001). There was no difference in the updated HbA1c and retinopathy between the two groups.  However, the younger group had more albuminuria (p=0.01) and neuropathy (p=0.002). The deceased young onset individuals could not be distinguished from the survivors by any clinical criteria at their first visit but at the last visit before death, the deceased group had more albuminuria, hypertension, peripheral artery disease and stroke (p=0.01).

Conclusion: We conclude that individuals with young onset Type 2 diabetes suffer at least a 16 years excessive loss in life expectancy. Their cardiovascular risk factors should be treated more intensively.

Nothing to Disclose: AHA, MC, LM, FG, FG, CL, TW, SMT, DY, JW

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm